The integration of molecular diagnostics with therapeutics: Implications for drug development and pathology practice

American Journal of Clinical Pathology

Volumn 119, Issue 1, 2003, Pages 26-36

  Ross, Jeffrey S ^a,b   Ginsburg, Geoffrey S ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cancer predisposition; Molecular diagnostics; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Productivity; Toxicogenomics

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; BRCA2 PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; MERCAPTOPURINE; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; TACRINE; TAMOXIFEN; TAXANE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; UNINDEXED DRUG; WARFARIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BREAST CANCER; CANCER; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COLORECTAL CANCER; DEPRESSION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DNA MICROARRAY; DNA PROBE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENOMICS; GENOTYPE; HUMAN; HYPERLIPIDEMIA; INFECTION; LEUKEMIA; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; NEPHROBLASTOMA; ONCOGENE NEU; OSTEOPOROSIS; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; THROMBOEMBOLISM; TOXICITY TESTING; TUMOR SUPPRESSOR GENE; CLINICAL MEDICINE; DRUG DESIGN; GENETIC PREDISPOSITION; METHODOLOGY; PATHOLOGY;

CLINICAL MEDICINE; DRUG DESIGN; DRUG INDUSTRY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PATHOLOGY, CLINICAL; PHARMACOGENETICS;

EID: 85047686947     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/VMLL66Y5KHQ35KUE     Document Type: Review

References (100)

1. Keesee SK. Molecular diagnostics: impact upon cancer detection. Expert Rev Mol Diagn. 2002;2:91-92.
2. Poste G. Molecular diagnostics: a powerful new component of the healthcare value chain. Expert Rev Mol Diagn. 2001;1:1-5.
3. Leonard DG. The present and future of molecular diagnostics. Mol Diagn. 2001;6:71-72.
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
5. O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol. 2000;1:207-211.
6. Amos J, Patnaik M. Commercial molecular diagnostics in the US: the Human Genome Project to the clinical laboratory. Hum Mutat. 2002;19:324-333.
7. Bottles K. A revolution in genetics: changing medicine, changing lives. Physician Exec. 2001;27:58-63.
8. Halapi E, Hakonarson H. Advances in the development of genetic markers for the diagnosis of disease and drug response. Expert Rev Mol Diagn. 2002;2:411-421.
9. Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935-941.
10. Suh DC, Woodall BS, Shin SK, et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34:1373-1379.
11. du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol. 2001;8:153-161.
12. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19:491-496.
13. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237-252.
14. Morgan GJ, Pratt G. Modern molecular diagnostics and the management of haematological malignancies. Clin Lab Haematol. 1998;20:135-141.
15. Zareba W, Moss AJ, Schwarts PJ, et al, for the International Long Q-T Syndrome Registry Research Group. Influence of genotype on clinical course of the long-QT syndrome. N Engl J Med. 1998;339:960-965.
16. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 as well as LQT3 models of the long-QT syndrome. Circulation. 1997;96:2038-2047.
17. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92:3381-3386.
18. Jordan VC. Progress in the prevention of breast cancer: concept to reality. J Steroid Biochem Mol Biol. 2000;74:269-277.
19. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update. 2000;6:419-426.
20. Crouch MA. Effective use of statins to prevent coronary heart disease. Am Fam Physician. 2001;63:309-320.
21. Taylor JG, Choi EH, Foster CB, et al. Using genetic variation to study human disease. Trends Mol Med. 2001;7:507-512.
22. Carlson CS, Newman TL, Nickerson DA. SNPing in the human genome. Curr Opin Chem Biol. 2001;5:78-85.
23. Griffin TJ, Smith LM. Single-nucleotide polymorphism analysis by MALDI TOF mass spectrometry. Trends Biotechnol. 2000;18:77-84.
24. Kallioniemi OP. Biochip technologies in cancer research. Ann Med. 2001;33:142-147.
25. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99-108.
26. Borg A. Molecular and pathological characterization of inherited breast cancer. Semin Cancer Biol. 2001;11:375-385.
27. Renegar G, Rieser P, Manasco P. Pharmacogenetics: the Rx perspective. Expert Rev Mol Diagn. 2001;1:255-263.
28. Jass JR. Familial colorectal cancer: pathology and molecular characteristics. Lancet Oncol. 2000;1:220-226.
29. Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. Anticancer Res. 2001;21:3631-3635.
30. Calzone KA, Biesecker BB. Genetic testing for cancer predisposition. Cancer Nurs. 2002;25:15-25.
31. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants: the role of the CYP family of enzymes. Mutat Res. 2001;482:11-19.
32. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250:186-200.
33. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 2002;315:137-155.
34. Roses AD. Pharmacogenetics. Hum Mol Genet. 2001;10:2261-2267.
35. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000;61:199-203.
36. Gold B. DNA genotyping. Adv Clin Chem. 2001;36:171-234.
37. Linder MW, Valdes R Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol. 2001;25:405-413.
38. Danesi R, De Braud F, Fogli S, et al. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci. 2001;22:420-426.
39. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65-70.
40. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-2199.
41. Rusnak JM, Kisabeth RM, Herbert DP, et al. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. Mayo Clin Proc. 2001;76:299-309.
42. Hess P, Cooper D. Impact of pharmacogenomics on the clinical laboratory. Mol Diagn. 1999;4:289-298.
43. Harkin DP. Uncovering functionally relevant signaling pathways using microarray based expression profiling. Oncologist. 2000;5:501-507.
44. Snijders AM, Meijer GA, Brakenhoff RH, et al. Microarray techniques in pathology: tool or toy? Mol Pathol. 2000;53:289-294.
45. Raetz EA, Moos PJ, Szabo A, et al. Gene expression profiling: methods and clinical applications in oncology. Hematol Oncol Clin North Am. 2001;15:911-930.
46. Polyak K, Riggins GJ. Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J Clin Oncol. 2001;19:2948-2958.
47. Lewis F, Maughan NJ, Smith V, et al. Unlocking the archive gene expression in paraffin-embedded tissue. J Pathol. 2001;195:66-71.
48. Maughan NJ, Lewis FA, Smith V. An introduction to arrays. J Pathol. 2001;195:3-6.
49. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195:41-52.
50. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20:1932-1941.
51. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-470.
52. Zanders ED. Gene expression analysis as an aid to the identification of drug targets. Pharmacogenomics. 2000;1:375-384.
53. Weinstein JN. Pharmacogenomics: teaching old drugs new tricks [editorial]. N Engl J Med. 2000;343:1408-1409.
54. Chicurel ME, Dalma-Weiszhausz DD. Microarrays in pharmacogenomics: advances and future promise. Pharmacogenomics. 2002;3:589-601.
55. Los G, Yang F, Samimi G, et al. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry. 2002;47:66-71.
56. Slonim DK. Transcriptional profiling in cancer: the path to clinical pharmacogenomics. Pharmacogenomics. 2001;2:123-136.
57. Dougherty ER, Barrera J, Brun M, et al. Inference from clustering with application to gene-expression microarrays. J Comput Biol. 2002;9:105-126.
58. Fryer RM, Randall J, Yoshida T, et al. Global analysis of gene expression: methods, interpretation, and pitfalls. Exp Nephrol. 2002;10:64-74.
59. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673-683.
60. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9-16.
61. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol. 2001;116:637-646.
62. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124.
63. Hamadeh HK, Bushel P, Paules R, et al. Discovery in toxicology: mediation by gene expression array technology. J Biochem Mol Toxicol. 2001;15:231-242.
64. Fielden MR, Zacharewski TR. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci. 2001;60:6-10.
65. Burchiel SW, Knall CM, Davis JW II, et al. Analysis of genetic and epigenetic mechanisms of toxicity: potential roles of toxicogenomics and proteomics in toxicology. Toxicol Sci. 2001;59:193-195.
66. Hamadeh HK, Amin RP, Paules RS, et al. An overview of toxicogenomics. Curr Issues Mol Biol. 2002;4:45-56.
67. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000;97:12329-12333.
68. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
69. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer. 2001;2:129-137.
70. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med. 2002;8(4 suppl):S14-S18.
71. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin. 2002;97(suppl 1):28-30.
72. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes [editorial]. J Clin Oncol. 2002;20:2217-2219.
73. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2:278-289.
74. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29:27-36.
75. McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100.
76. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13:522-527.
77. Piecyk M, Anderson P. Signal transduction in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15:789-803.
78. Williamson AA, McColl GJ. Early rheumatoid arthritis: can we predict its outcome? Intern Med J. 2001;31:168-180.
79. Watts DA, Satsangi J. The genetic jigsaw of inflammatory bowel disease. Gut. 2002;50(suppl 3):III31-III36.
80. Satsangi J. Genetics of inflammatory bowel disease: from bench to bedside? Acta Odontol Scand. 2001;59:187-192.
81. Patel VB, Robbins MA, Topol EJ. C-reactive protein: a "golden marker" for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68:521-524.
82. Feinstein SB, Voci P, Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am J Cardiol. 2002;89:31C-43C.
83. Stein E. Laboratory surrogates for anti-atherosclerotic drug development. Am J Cardiol. 2001;87:21A-26A.
84. McCarthy MI, Hattersley AT. Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes. Expert Rev Mol Diagn. 2001;1:403-412.
85. Berger A, Preiser W. Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. J Antimicrob Chemother. 2002;49:713-721.
86. Vandamme AM, Houyez F, Banhegyi D, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther. 2001;6:21-39.
87. Buss N, Cammack N. Measuring the effectiveness of antiretroviral agents. Antivir Ther. 2001;6:1-7.
88. Russo A, Zanna I, Tubiolo C, et al. Hereditary common cancers: molecular and clinical genetics. Anticancer Res. 2000;20:4841-4851.
89. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17:123-128.
90. Ross JS. Economic, regulatory, and practice issues in molecular pathology and diagnostics. Am J Clin Pathol. 1999;112(1 suppl 1):S7-S10.
91. Sakallah SA. Molecular diagnostics of infectious diseases: state of the technology. Biotechnol Annu Rev. 2000;6:141-161.
92. Pang CP. Molecular diagnostics for cardiovascular disease. Clin Chem Lab Med. 1998;36:605-614.
93. Lacroix J, Doeberitz MK. Technical aspects of minimal residual disease detection in carcinoma patients. Semin Surg Oncol. 2001;20:252-264.
94. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin Chem. 2002;48:1178-1185.
95. Jain KK. Applications of proteomics in oncology. Pharmacogenomics. 2000;1:385-393.
96. Lee KH. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol. 2001;19:217-222.
97. Herrmann PC, Liotta LA, Petricoin EF III. Cancer proteomics: the state of the art. Dis Markers. 2001;17:49-57.
98. Srinivas PR, Srivastava S, Hanash S, et al. Proteomics in early detection of cancer. Clin Chem. 2001;47:1901-1911.
99. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
100. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661-681.